Can Peptides Crack the Biofilm Code?

An $88M raise sends Peptilogics into a pivotal trial targeting stubborn prosthetic joint infections 

16 Feb 2026

A high-stakes bet is taking shape in the fight against stubborn surgical infections.

Peptilogics has raised $88 million to push its lead engineered peptide, zaloganan, into a pivotal Phase 2/3 trial for prosthetic joint infections. The condition is one of the most vexing complications in orthopedic care, often surfacing after hip and knee replacements and refusing to clear with standard antibiotics.

The round, backed by Thiel Bio and Founders Fund, signals growing confidence that peptide drugs could change how medicine tackles infections that hide in plain sight.

The problem lies in biofilms. These slimy bacterial fortresses cling to implanted devices, shielding microbes from antibiotics and the immune system. Once established, they can linger for months or years. Patients frequently endure repeat surgeries, long hospital stays, and extended antibiotic courses. Per-case costs can exceed $50,000, yet no therapy is approved specifically to dismantle biofilm-driven infections.

Zaloganan is designed to breach that shield. By directly targeting bacteria embedded within biofilms, the drug aims to do what conventional treatments struggle to accomplish.

Reaching a pivotal trial is a defining moment for any young biotech company. Late-stage studies are expensive and unforgiving, but they are the gateway to regulatory approval and, ultimately, the market. For Peptilogics, the financing provides runway and signals investor belief that the science can hold up under scrutiny.

The raise also fits into a broader resurgence of interest in peptide-based medicines. Successes in other fields have revived enthusiasm for the modality, encouraging investors to fund more ambitious programs in infectious disease.

Still, enthusiasm is not the same as evidence. The trial must show clear advantages over surgery and systemic antibiotics, the current standard of care. Pricing and reimbursement will also shape how widely the therapy is adopted if it wins approval.

For now, the spotlight is on the data to come. As antimicrobial resistance rises and healthcare systems grapple with mounting costs, a therapy that can dismantle biofilms could shift the balance. This trial is more than a company milestone. It is a referendum on whether engineered peptides can rewrite the rules of infection treatment.